Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced that it has submitted purchase orders for the acquisition of custom-made, semi-automatic filling equipment for the large-scale commercial production of Oral-lyn™, the Company’s proprietary oral insulin spray product, which is delivered into the human mouth by way of the Company’s proprietary RapidMist™ drug delivery system. The equipment will be used in the Company’s launch of the product in Ecuador at the end of this month. Oral-lyn™ has been approved for commercial marketing and sale by the Ecuadorian Ministry of Public Health for the treatment of both Type-1 and Type-2 diabetes. The Company and PharmaBrand, S.A. (www.pharmabrand.com.ec), the Company’s South American joint venture partner in Quito, Ecuador, are making preparations for the launch of commercial sales. Oral-lyn™ is the only non-injectable form of insulin approved for sale anywhere in the world.
